Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- 1st Qtr Business Results
August 29, 2005
- Caiapo Launched in Australia, New Zealand
August 29, 2005
- All-case PMS Completed for Remicade; Tanabe to Gear Up Promotion
August 22, 2005
- Osaka Gov't Brings Lawsuits Demanding Payment of Copayments
August 22, 2005
- Taisho to Launch Switch-OTC Version of Novartis' Zaditen
August 22, 2005
- Uncollected Medical Fees - Why Don't Patients Pay?
August 22, 2005
- Bushu Pharm. to Start Independent PR Activities
August 22, 2005
- Approval of 5 Anticancer Agents Discussed
August 22, 2005
- BUSINESS NEWS IN BRIEF
August 22, 2005
- Nippon Chemiphar Announces New 3-Year Management Plan
August 22, 2005
- More than 400 Medical Institutions Issue GE Name Prescriptions
August 22, 2005
- MediciNova Starts PII Trial of Ibudilast for MS
August 22, 2005
- Burgeoning Clinical Trial Business in China
August 22, 2005
- 1st Qtr Business Results
August 22, 2005
- NEW PRODUCTS
August 22, 2005
- Associations Petition for Rapid Increase in Review Staff
August 22, 2005
- Olympus, Terumo to Develop New Medical Devices Based on Capital Alliance
August 22, 2005
- SELF-MEDICATION
August 22, 2005
- Retirees Drove Growth in Medical Expenditure in FY2004: Survey
August 22, 2005
- Council Calls for More Screening of Hepatitis C
August 22, 2005
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…